Thrivent Financial for Lutherans lowered its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 44.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,619 shares of the specialty pharmaceutical company's stock after selling 11,574 shares during the quarter. Thrivent Financial for Lutherans' holdings in Jazz Pharmaceuticals were worth $1,629,000 at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. LSV Asset Management increased its stake in shares of Jazz Pharmaceuticals by 4.2% during the 2nd quarter. LSV Asset Management now owns 2,480,563 shares of the specialty pharmaceutical company's stock worth $264,750,000 after purchasing an additional 99,705 shares during the last quarter. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 40.7% during the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock worth $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Baupost Group LLC MA boosted its holdings in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock valued at $136,000,000 after acquiring an additional 440,552 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Jazz Pharmaceuticals by 48.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,222,198 shares of the specialty pharmaceutical company's stock valued at $130,447,000 after purchasing an additional 398,549 shares during the last quarter. Finally, Swedbank AB bought a new position in shares of Jazz Pharmaceuticals in the second quarter worth about $106,936,000. 89.14% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
JAZZ has been the subject of several recent analyst reports. TD Cowen decreased their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Piper Sandler restated an "overweight" rating and issued a $163.00 price objective (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. HC Wainwright reiterated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Cantor Fitzgerald reissued an "overweight" rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Finally, Robert W. Baird boosted their price objective on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday, November 18th. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $175.33.
Check Out Our Latest Report on Jazz Pharmaceuticals
Insider Transactions at Jazz Pharmaceuticals
In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now owns 14,531 shares of the company's stock, valued at $1,573,707.30. This represents a 8.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares of the company's stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,110 shares of company stock valued at $720,160 in the last three months. 4.20% of the stock is owned by corporate insiders.
Jazz Pharmaceuticals Price Performance
NASDAQ:JAZZ traded down $1.05 on Friday, reaching $121.59. The stock had a trading volume of 286,839 shares, compared to its average volume of 675,459. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. The stock has a fifty day moving average price of $114.87 and a 200-day moving average price of $111.12. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.
Jazz Pharmaceuticals Company Profile
(
Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
See Also
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.